New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
06:21 EDTMYGNMyriad Genetics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse upgraded Myriad Genetics to Neutral based on strong quarterly results and the Crescendo acquisition that adds diversification and accretion. Price target raised to $29 from $18.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use